Results 71 to 80 of about 43,946 (263)

Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity

Clinical Pharmacology &Therapeutics, EarlyView.
Cystic fibrosis (CF) is a chronic hereditary disease that affects tens of thousands of people worldwide. The introduction of CFTR modulator therapies such as elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved the quality of life of people with CF.
Alan Shi, Cole Cornwell, Kyunghee Yang, Paul M. Beringer   +3 more
wiley   +1 more source

Enzymatic digestion and selective quantification of underivatised [delta]9-tetrahydrocannabinol and cocaine in human hair using gas chromatography-mass spectrometry. [PDF]

, 2012
Gas chromatography-mass spectrometric (GC-MS) methods for drug analysis routinely employ derivatising reagents. The aim of this paper was to develop a method for the analysis of two recreational drugs, delta-9-tetrahydrocannabinol ([delta](9)-THC) and ...
Barker, James, Breidi, Salah Eddine, Naughton, Declan, Petroczi, Andrea   +3 more
core   +3 more sources

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey

Epilepsia Open, EarlyView.
Abstract Objective To assess the burden of Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS), including managing seizure and nonseizure symptoms, on patients and caregivers. Methods Data were drawn from the Adelphi Real World DS and LGS Disease Specific Programme™, a cross‐sectional survey in Asia (China, Japan), Europe (France, Germany, Italy ...
Drishti Shah, Vicente Villanueva, Dennis Dlugos, Arturo Benitez, Yasmin Taylor, Stevie Olsen, Hannah Connolly, Sophie Lai, J. Scott Andrews   +8 more
wiley   +1 more source

Canabidiol: de um canabinóide inativo a uma droga com amplo espectro de ação [PDF]

, 2008
OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO.
ZUARDI, Antonio Waldo
core   +2 more sources

Epileptic drop attacks: More than just atonic seizures

Epilepsia Open, EarlyView.
Abstract “Drop attacks” are not officially defined by the International League Against Epilepsy. Seizures are characterized by a sudden loss of control over the trunk and posture, leading to falls and injuries, and resolving within a few seconds. Accurately diagnosing the type of seizure is usually difficult due to limitations in clinical documentation
Tomonori Ono, Kazuaki Sato, Ryoko Honda, Hiroshi Otsubo   +3 more
wiley   +1 more source

Real‐world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies

Epilepsia Open, EarlyView.
Abstract Objective Highly purified cannabidiol (CBD) is approved as adjunctive therapy for seizures associated with Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC), although its role in other developmental and epileptic encephalopathies (DEEs) remains unexplored.
Marco Perulli, Maddalena Bianchetti, Gloria Pantalone, Michela Quintiliani, Maria Luigia Gambardella, Maria Picilli, Carla Marini, Elisabetta Cesaroni, Domenica Immacolata Battaglia   +8 more
wiley   +1 more source

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment

Journal of Neurodevelopmental Disorders, 2023
Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS).
Joseph M. Palumbo, Brian F. Thomas, Dejan Budimirovic, Steven Siegel, Flora Tassone, Randi Hagerman, Christopher Faulk, Stephen O’Quinn, Terri Sebree   +8 more
doaj   +1 more source

Lennox-Gastaut Syndrome: A State of the Art Review. [PDF]

, 2017
Lennox-Gastaut syndrome (LGS) is a severe age-dependent epileptic encephalopathy usually with onset between 1 and 8 years of age. Functional neuroimaging studies recently introduced the concept of Lennox-Gastaut as "secondary network epilepsy" resulting ...
Mastrangelo, Mario
core   +1 more source

Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study

Epilepsia Open, EarlyView.
Abstract Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐approval in the USA remain insufficiently characterized.
Elaine Wirrell, James Wheless, Michael Scott Perry, Linda Laux, Karen C. Keough, Julie Ziobro, Aimee F. Luat, Gewalin Aungaroon, Michael A. Ciliberto, Roxane Noel, Laurent Chancharme, Joseph Sullivan   +11 more
wiley   +1 more source